Clinical impact of elevated tricuspid valve inflow gradients after transcatheter edge-to-edge tricuspid valve repair.
The aim of this study was to compare outcome of patients with a post-procedural tricuspid valve gradient (TVG) of &gt;3 mmHg vs. ≤3 mmHg after transcatheter edge-to-edge tricuspid valve repair (TTVR). Between March 2016 and October 2018 we treated 145 patients with severe tricuspid regurgitation (TR) with TTVR by placing 2.2±0.7 clips per patient. Device success (TR reduction ≥1° to at least moderate) was achieved in 125 patients (86.2%). TTVR resulted in an elevated TVG &gt;3 mmHg in 25 (17.2%) patients. Device success (84% vs. 86.7%, p=0.9), number of clips implanted (2.3±0.7 vs. 2.2±0.7, p=0.33), clinical improvement including NYHA class (III/IV 24% vs. 28%, p=0.92) and increase in 6 minute walking test at 1 month (67 m [IQR 5-103 m] vs. 56 m [IQR 8-97 m], p=0.93), mortality (HR 1.07; 95% CI [0.43-2.65], plogrank=0.88) and the combined endpoint mortality and hospitalization for heart failure at one year (HR 1.07; 95% CI [0.46-2.48], plogrank=0.88) was similar between patients with a TVG &gt;3 mmHg vs. patients with a TVG ≤3mmHg. A small cohort of patients demonstrated with an elevated TVG higher than 3 mmHg at discharge. This elevation had no impact on clinical improvement, on mortality and hospitalization for heart failure.